Oral Drug Combination Eases Treatment Burden for AML Patients | Newsroom
A significant shift in the treatment of acute myeloid leukemia (AML) has emerged following the results of the ASCERTAIN V clinical trial. The study demonstrates that an all-oral drug combination provides an effective alternative to the traditional standard of care, which typically requires frequent hospitalizations for intravenous treatment.
The trial, led by researchers from Weill Cornell Medicine, NewYork-Presbyterian, Yale University, and The University of Texas MD Anderson Cancer Center, tested a regimen combining two pills: venetoclax and decitabine-cedazuridine. Results published June 3 in the New England Journal of Medicine indicate strong response rates and survival outcomes for patients.
Specifically, 46.5% of patients achieved a complete response. 63% experienced either a complete response or a complete response with incomplete hematologic recovery, a state where cancer cells are undetectable although healthy blood cell counts have not yet fully returned to normal.
FDA Approval and Market Significance
On May 13, the U.S. Food and Drug Administration approved the combination of decitabine-cedazuridine and venetoclax. This approval applies to newly diagnosed adults aged 75 years or older, as well as patients who are clinically unable to undergo traditional, intensive chemotherapy.
The median overall survival for patients in the trial reached 15.5 months, a figure comparable to existing intravenous therapies. According to lead author Dr. Gail J. Roboz, this oral regimen is anticipated to become the standard of care for older or more frail patients.
The business and logistical implications are substantial. The previous standard required monthly cycles involving five to seven days of injectable hypomethylating agents delivered in a clinic or hospital, creating significant emotional and physical burdens for families.
Clinical Mechanics and Safety
The treatment works through a dual-action approach. Venetoclax inhibits Bcl-2, a protein that leukemia cells use to avoid death, while hypomethylating agents restore genes involved in cell growth and survival to slow the progression of the cancer.
The ASCERTAIN V trial, which enrolled 189 patients across Spain, Canada, and the United States, found a safety profile consistent with standard AML therapies. Common serious side effects included neutropenia, anemia, and fever associated with low white blood cell counts.
To manage these effects, researchers suggested that physicians strategically pause venetoclax based on leukemia cell thresholds. This approach is intended to allow the body to replenish platelets, red blood cells, and white blood cells.
Future Outlook and Potential Developments
Currently, most patients using the oral regimen must continue treatment to maintain remission, treating the cancer similarly to a chronic condition. However, the researchers suggest that more sensitive blood monitoring tests may eventually identify when patients can safely stop treatment.
A possible next step in treatment evolution involves “triplet therapies.” Researchers are exploring the addition of further targeted drugs to the existing decitabine-cedazuridine and venetoclax combination.
The ultimate goal of these advancements may be to reduce leukemic cells to such low levels that patients could potentially discontinue therapy and be cured, moving away from indefinite treatment cycles.
The ASCERTAIN V research was funded by Taiho Oncology, Inc., the manufacturer of INQOVI® (decitabine-cedazuridine).
Frequently Asked Questions
Who is eligible for this newly approved oral AML treatment?
The treatment is approved for newly diagnosed adults aged 75 years or older and patients who are clinically unable to undergo traditional, intensive chemotherapy.
How does the oral regimen compare to intravenous therapy in terms of survival?
The median overall survival for the oral regimen was 15.5 months, which is comparable to existing intravenous therapies.
What are the primary side effects associated with this treatment?
The most common serious side effects include anemia (low red blood cell count), neutropenia (low white blood cell count), and fever associated with low white blood cell numbers.
How do you think the shift toward home-based oral treatments will impact the quality of life for elderly patients facing chronic illnesses?